Group items tagged

MaRS, a non-profit, collaborative entity of the university, provincial and federal governments and industry, which aims to turn these discoveries into commercial projects.

MaRS, a non-profit, collaborative entity of the university, provincial and federal governments and industry, which aims to turn these discoveries into commercial projects.

MaRS, a non-profit, collaborative entity of the university, provincial and federal governments and industry, which aims to turn these discoveries into commercial projects.

the Chief of Research at the Hospital for Sick Children in Toronto, collaboration is the key to the future.

That's why Dr. Janet Rossant is so enthusiastic about the work being done in the MaRS Discovery District - a unique zone in the city where innovations in science and technology are commercialized through partnerships between researchers and private enterprise.

"The MaRS Centre and biomedical community have seen tremendous growth over the past few years," says Dr. Janet Rossant. "And it continues to grow." "This growth is attracting the world's best scientists to come work here, which is very exciting."

The Ivey Centre for Health Innovation and Leadership was launched this year with a $5-million push from the Canadian government. The latest Ivey initiative has the goal of bringing students together with experts from the science and business sectors, with the ultimate goal of better identifying and commercializing health technologies.Dr. Kellie Leitch, a Hospital for Sick Children orthopedic surgeon, is the first executive director of the centre, which is based at Western.

She is sitting in the basement of MaRS, a scientific hub of activity in downtown Toronto where labs, business and major Toronto teaching hospitals are brought together under one roof.

The Ivey centre will focus on giving the educational capability to our students so they become really well educated in innovation and commercialization, so we can keep things here at home in Canada and grow those products."

MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.

With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Rafi Hofstein, President and CEO of MaRS Innovation.

MaRS Innovation, along with the inventors and Mount Sinai, will initially focus on the diabetes application for the technology, as research has demonstrated that these cells uniquely secrete insulin in response to glucose, thereby mimicking the “normal” physiological state.

Canada has always had to fight hard to attract talent and investment

MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.

"We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.

Canada's economy is outperforming the rest of the developed world

willingness to embrace a strong role for public investment in innovation,

Another example of public, private and university collaboration is the MaRS discovery district, a nonprofit innovation center that brings together biotech researchers, VCs, and social entrepreneurs in the same part of downtown Toronto with several research hospitals. 

MaRS aggregates the discovery pipelines of its member institutions, which include three universities, 10 academic teaching hospitals, and the Ontario Institute for Cancer Research.

MaRS is another good example. Located in the heart of downtown Toronto, the MaRS facility is less than a mile from five major teaching hospitals, the Ontario legislature, and the University of Toronto. More than two dozen research institutes and Toronto’s financial district are also nearby.

Consequently, MaRS is a vertical incubator, with a wide variety of companies and stages of development. That mix helps companies better understand the conditions that foster growth. MaRS is home to more than 65 organizations, including The Hospital for Sick Children, the Ontario Institute for Cancer Research, Merck Frosst Canada, the McEwen Centre for Regenerative Medicine, Celtic House Venture Partners, AIM Therapeutics, and AstraZeneca Canada.

MaRS Innovation is honoured to announce its permanent Board of Directors, who brings together a remarkable and broad set of experiences and networks to support the development of this dynamic partnership of Toronto research institutions.  Designed to enhance the commercial output of Toronto’s world-leading research cluster, MaRS Innovation is positioned to make a significant contribution to Canada’s innovation economy and the quality of life for Canadians and others around the world.

upported by the Government of Canada through the Centres of Excellence in Research and Commercialization (CECR) program, and its member institutions, MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. The newly appointed Board of Directors, which includes academic and business leaders from across Canada and the United States, has the targeted expertise to guide MaRS Innovation to deliver on this critical mission.   MaRS Innovation represents a unique collaborative model, which aggregates the exceptional discovery pipeline of 14 leading Toronto academic institutions to build a diversified portfolio of assets, and harness the economic and job creation potential of the best opportunities for Toronto, Ontario and Canada.

“MaRS Innovation is privileged to announce a Board of Directors of this caliber and breadth of skill,” said Mary Jo Haddad, Chair of the MaRS Innovation Board and President and CEO of The Hospital for Sick Children. “The collective experience and guidance of these individuals will be critical to developing a collaborative, integrated and agile approach to this transformational organization that will move Canada into its next phase of economic development.”

Ontario is providing

$1 million in seed money to back one of last year's most exciting medical breakthroughs, turning simple skin cells into stem cells.

A lab run by the Hospital for Sick Children and the University of Toronto in the MaRS (Medical and Related Sciences) complex on College St. has developed the expertise to grow the cells in quantity and is ready to roll.

Probably most impressive was The MaRS Centre - an old hospital converted into a non-profit innovation centre connecting science, technology and social entrepreneurs with business skills, networks and capital. The building is undeniably cool. Located in Toronto’s “Discovery District” -- two square kilometres have been designated as the city’s center of innovation. The MaRS Centre is a gateway of sorts to Canada’s largest concentration of scientific research. It’s anchored by major teaching hospitals, the University of Toronto and more than two dozen affiliated research institutes.

MaRS Centre from the outside

MaRS was created in 2000. The founding group raised significant capital (almost $100 million from all three levels of government and both institutional and individual private sector donors and an additional $130 million of debt and credit lease instruments were also secured) to support the development. What’s so clear is that leadership to drive public/private sector collaboration is required to effect real change. Many credit Ontario Premier Dalton McGuinty for helping to not only create the MaRS Centre but also invigorate the region as a whole.